BridgeBio Pharma, Inc. — Form 10-Q Summary
Business context and reporting period
BridgeBio is a commercial-stage biopharmaceutical company developing medicines for genetically driven diseases and cancers. The filing covers the unaudited three and six months ended June 30, 2023, compared with the corresponding 2022 periods. The company reports more than 15 ongoing clinical trials across over 20 disease states and has not generated significant product-sales revenue.
Key financial metrics
| Metric | Three months ended June 30, 2023 | Six months ended June 30, 2023 |
|---|---|---|
| Revenue | $1.6 million | $3.5 million |
| Gross profit | $1.0 million | $2.2 million |
| Gross margin | Approximately 63.5% | Approximately 63.9% |
| Research and development expense | $107.5 million | $200.3 million |
| SG&A expense | $36.1 million | $67.2 million |
| Restructuring, impairment and related charges | $3.5 million | $6.9 million |
| Loss from operations | $146.1 million | $272.3 million |
| Net loss | $160.7 million | $303.4 million |
| Net loss attributable to BridgeBio common stockholders | $157.9 million, or $0.98 per share | $298.1 million, or $1.90 per share |
| Net cash used in operating activities | Not separately provided | $257.7 million |
- Cash and cash equivalents were $302.4 million at June 30, 2023; marketable securities were $30.9 million, restricted cash was $19.9 million, and equity investments were $50.5 million.
- Total cash, cash equivalents and restricted cash were $324.6 million at June 30, 2023, down from $416.9 million at December 31, 2022.
- Debt carrying values totaled approximately $1.72 billion, consisting of $735.9 million of 2029 Notes, $542.5 million of 2027 Notes and $440.5 million of term loan debt.
- The 2029 Notes have a $747.5 million principal balance and mature in 2029; the 2027 Notes have a $550.0 million principal balance and mature in 2027. The secured term loan had approximately $452.0 million of principal and matures in November 2026.
- Financing activities provided $149.0 million in the first half of 2023, primarily from the March follow-on offering. Investing activities provided $16.4 million.
Material changes versus the prior comparable period
- Revenue declined $72.1 million, or approximately 98%, in both the quarter and first half, primarily because the prior-year periods included $70.2 million of license revenue from the Navire-BMS transaction. 2023 revenue mainly reflected ongoing services under that agreement.
- First-half net loss increased to $303.4 million from $203.9 million, and quarterly net loss increased to $160.7 million from $2.6 million. The 2022 period benefited from a $107.9 million net gain on the sale of a priority review voucher.
- First-half research and development expense decreased $15.7 million, and SG&A decreased $12.9 million, mainly due to program reprioritization and restructuring-related cost reductions.
- Restructuring charges decreased $24.2 million year over year to $6.9 million, compared with $31.1 million in the first half of 2022, which included significant impairments and severance costs.
- Operating cash burn increased to $257.7 million from $191.1 million, while cash and restricted cash decreased $92.2 million during the first half of 2023.
- In March 2023, the FDA permanently discontinued distribution of TRUSELTIQ and discontinued associated clinical investigations because of difficulty enrolling the required confirmation trial. Helsinn completed product sales in the first quarter, and future oncology milestone rights under the terminated agreement were eliminated.
- BridgeBio deconsolidated PellePharm during the first quarter and recognized a $1.2 million loss.
Guidance, outlook, risks and unusual items
- Management does not anticipate product-sales revenue for the remainder of 2023 because selling activities for approved products have been transferred or transitioned to partners.
- Management expects operating and net losses to continue for at least the next several years and expects to incur substantial costs as programs advance through later-stage clinical trials.
- Management expects restructuring charges of approximately $7.0 million to $9.0 million for fiscal 2023, subject to assumptions and possible additional costs.
- Management states that cash, cash equivalents, marketable securities, restricted cash and equity investments are expected to fund operations for at least the next 12 months from the filing date under current plans. Additional financing may be required sooner if operating plans change.
- Liquidity is constrained by substantial clinical-development cash requirements, approximately $1.72 billion of debt carrying value, fixed interest obligations, term-loan covenants and mandatory-prepayment provisions related to certain monetization or licensing transactions.
- Potential milestone compensation obligations totaled $193.4 million at June 30, 2023, of which $12.7 million was accrued as probable.
- Key risks include clinical and regulatory failure, enrollment delays, dependence on third-party manufacturers and research organizations, intellectual-property disputes, financing availability, financial-institution liquidity events, inflation, interest rates and equity-price volatility.
- In July 2023, the company sold 800,000 shares through its ATM program for net proceeds of $27.2 million, increasing liquidity but diluting existing holders.
Important facts for investors to verify
- Confirm the timing and outcome of pivotal clinical and regulatory milestones, particularly for acoramidis, low-dose infigratinib, BBP-418, encaleret and other priority programs.
- Assess whether the stated 12-month liquidity runway remains adequate after ongoing operating cash burn, debt service, development spending and restricted cash requirements.
- Review the 2027 Notes maturity, the November 2026 term-loan maturity, PIK interest accumulation and applicable covenant or mandatory-prepayment provisions.
- Track use of the $450 million ATM facility, additional equity issuance and resulting dilution.
- Evaluate the likelihood and timing of licensing milestones, royalties or collaboration payments, recognizing that management has constrained substantially all variable consideration.
- Monitor restructuring completion, remaining liabilities and any further program reprioritization or asset impairments.
- Verify the impact of the TRUSELTIQ discontinuation and Helsinn termination on future revenue, expenses and development strategy.